Trademark: 90672395
Word
EMPOUIK
Status
Dead
Status Code
606
Status Date
Monday, October 2, 2023
Serial Number
90672395
Mark Type
3000
Filing Date
Monday, April 26, 2021
Published for Opposition
Tuesday, January 3, 2023
Abandoned Date
Monday, October 2, 2023

Trademark Owner History
Bristol-Myers Squibb Company - Owner At Publication

Classifications
5 Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders
The mark consists of the word "EMPOUIK" in stylized font with curved lines above and below the letter "E".
Color is not claimed as a feature of the mark.

Trademark Events
Oct 2, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Oct 2, 2023
Abandonment - No Use Statement Filed
Aug 2, 2023
Teas Change Of Correspondence Received
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Owner Address Received
Feb 28, 2023
Noa E-Mailed - Sou Required From Applicant
Jan 3, 2023
Official Gazette Publication Confirmation E-Mailed
Jan 3, 2023
Published For Opposition
Dec 14, 2022
Notification Of Notice Of Publication E-Mailed
Nov 25, 2022
Notice Of Reinstatement E-Mailed
Nov 23, 2022
Approved For Pub - Principal Register
Nov 23, 2022
Examiner's Amendment Entered
Nov 23, 2022
Notification Of Examiners Amendment E-Mailed
Nov 23, 2022
Examiners Amendment E-Mailed
Nov 23, 2022
Examiners Amendment -Written
Nov 21, 2022
Reinstatement Granted - Inadvertently Abandoned
Nov 21, 2022
Abandonment Notice Mailed - Failure To Respond
Nov 21, 2022
Abandonment - Failure To Respond Or Late Response
May 3, 2022
Notification Of Final Refusal Emailed
May 3, 2022
Final Refusal E-Mailed
May 3, 2022
Final Refusal Written
Apr 6, 2022
Teas/Email Correspondence Entered
Apr 6, 2022
Correspondence Received In Law Office
Apr 6, 2022
Teas Response To Office Action Received
Oct 8, 2021
Notification Of Priority Action E-Mailed
Oct 8, 2021
Priority Action E-Mailed
Oct 8, 2021
Priority Action Written
Oct 5, 2021
Assigned To Examiner
Aug 3, 2021
Notice Of Design Search Code E-Mailed
Jul 31, 2021
New Application Office Supplied Data Entered
Apr 29, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24